The U.S. Food and Drug Administration is poised to make a decision on another new Alzheimer’s disease treatment this week, and experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available to explain how the drug works and which patients could benefit from the medication.
Research at Roswell Park Comprehensive Cancer Center shows that putting a three-day limit on opioid prescriptions to treat surgical pain after hospital discharge reduces the number of patients who become chronic opioid users without compromising pain relief or recovery. It also reduces the amount of opioids circulating in the community — a grave concern, given that opioids are implicated in 130 overdose deaths in the U.S. every day.
A chemistry collaboration led to a creative way to put carbon dioxide to good – and even healthy – use: by incorporating it, via electrosynthesis, into a series of organic molecules that are vital to pharmaceutical development.
Scientists from St. Jude Children’s Research Hospital performed the largest study yet examining drug sensitivity in childhood acute lymphoblastic leukemia across genomic subtypes and its association with treatment response.
Wayne State's Dr. Jamesdaniel received a $1.7 million NIH grant to study cisplatin, a drug that is prescribed to 10 to 20% of cancer patients that causes hearing loss in up to 80% treated with the drug.
Newly published research out of the University of Cincinnati and the University of California-Davis shows that direct oral anticoagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.
Research has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the liver, could be reversed with a single drug. The study, published in the Proceedings of the National Academy of Sciences, has the potential to transform treatment for this rare disease and may also have implications for more common diseases.
Following a modified Atkins diet high in fat and low in carbohydrates plus taking medication may reduce seizures in people with tough-to-treat epilepsy, according to a study published in the January 4, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A team from 15 U.S. medical centers led by UT Southwestern Simmons Cancer Center researchers has performed the first analysis of a potentially game-changing drug to treat upper urinary tract urothelial cancers.
SLAS, the Society of Laboratory Automation and Screening, announces the addition of three new board members who will carry out three-year terms beginning January 1, 2023.
Insulin is an essential hormone for humans and many other living creatures. Its best-known task is to regulate sugar metabolism. How it does this job is well understood.
Stuart Therapeutics, Inc., (hereinafter Stuart) announces that it has entered into a license agreement with AJU Pharm Co. Ltd. (hereinafter AJU), for Stuart's clinical stage drug candidate ST-100.
All patients undergoing procedures requiring anesthesia should be asked about cannabis use, according to guidelines released by the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine). The first U.S. guidelines on cannabis use in relation to surgery also notes regular use may worsen pain and nausea after surgery and increase the need for opioids.
Dr. Niklas Klümper, resident at the Clinic for Urology and working group leader at the Institute for Experimental Oncology at the University Hospital Bonn (UKB), was awarded the C. E. Alken Prize in recognition of his outstanding scientific uro-oncological work.
An international team of researchers including Sofya Kulikova, Senior Research Fellow at the HSE University-Perm, found that ketamine, being an NMDA receptor inhibitor, increases the brain's background noise, causing higher entropy of incoming sensory signals and disrupting their transmission between the thalamus and the cortex.
Clinical scientists with UC Davis and University of Cincinnati perform first-of-its-kind analysis showing a clear difference in cost-effectiveness of medication types for life-threatening condition
Columbia Engineering researchers report that they have developed a new experimental pipeline to combine bacterial therapy with current cancer drugs. Their study, which explores resistance to bacterial therapy at the molecular level, has achieved better treatment efficacy without additional toxicity in laboratory models.
Pathogens such as SARS-CoV-2 and pneumococcus can cause severe pneumonia. If the airways then fill with fluid, the patient risks developing acute respiratory distress syndrome.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
